Vivus' Qnexa Gets Advisory Committee; With Solid Efficacy Results, Issues May Be Safety-Related

The Endocrinologic and Metabolic Drugs Advisory Committee will review Vivus' obesity drug, Qnexa, a therapeutic class with cardiovascular risks.